Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
about
The interplay of post-translational modification and gene therapyDevelopments in the treatment of hemophilia B: focus on emerging gene therapyModulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors.Platelet-adenovirus vs. inert particles interaction: effect on aggregation and the role of platelet membrane receptors.Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.Adenoviral vector immunity: its implications and circumvention strategies.Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in miceThe influence of innate and pre-existing immunity on adenovirus therapyPre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster modelA porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease modelCurrent strategies and future directions for eluding adenoviral vector immunityAdenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirusHelper-dependent adenoviral vectors for liver-directed gene therapy.Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hostsEffect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vectorFiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.A novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expressionSTAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral ControlAn acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.Viral vector vaccines make memory T cells against malaria.Gene therapy applications for the treatment of neuropathic pain.In vivo Antitumor Effect of an HPV-specific Promoter driving IL-12 Expression in an HPV 16-positive Murine Model of Cervical Cancer.Gene and cell therapy for heart failure.Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.Improving adenovirus based gene transfer: strategies to accomplish immune evasion.Manipulation of adenovirus interactions with host factors for gene therapy applications.Gene therapy for the treatment of chronic peripheral nervous system pain.Biologic response of human intervertebral disc cells to gene therapy cocktail.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Preliminary evaluation of safety of conditionally replication adenovirus M4.Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1.Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver.Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents.Readministration of helper-dependent adenovirus to mouse lung.Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.Shutdown of immunological priming and presentation after in vivo administration of adenovirus.Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.
P2860
Q26751281-72C5A22C-338B-47ED-91E3-16B6586A6A6BQ26823376-54849A18-B50A-43D1-8A86-EF1DC030EA38Q33371239-43326863-5448-40BD-AEA6-0300F2494BBAQ33402442-9288F8C8-3BE4-4911-91AE-52FF22542A1DQ33434692-93DBF9B1-4BA9-40DE-909E-EE6A62D18EBFQ33565630-6CD0571A-4C58-430B-8410-F1E6308DBBD6Q33640779-FB87945E-30DC-4886-8839-52F2A1636C35Q33655401-82D0CC9D-8743-483A-8669-9E7BE3EFC0EAQ33713048-48F17C84-AD06-4466-ADE9-F77BCDADF316Q33778607-5B329785-D6CB-4BC0-B8E0-2A7E45BBFA00Q34585554-EBCF41E2-992B-4A45-95D5-2EB2106B5F33Q34717992-39FC8917-4A5B-483F-B7EE-4D8CBAE478DCQ34975214-59791B7A-C2E9-44BC-9361-C3AC89447CEDQ34982825-CC57C511-FF9C-4B0F-A39D-C462962954C7Q34984515-AB8BB498-2805-48FF-8A9C-65728C866DE6Q35022798-A7FD956B-6FFA-4326-AB14-90FC26AB8942Q35139196-9984C4C6-72FF-4E7E-B8AD-6A44D511E5C5Q35641856-B8F3A107-D1F6-4BB7-B7EB-DD82938B4325Q35751170-028D2164-5D02-417E-9118-AFA63A57DB86Q36209165-0ED0F14E-49FB-4DB7-924C-10EE5EB764B3Q36802741-9523279A-9B70-446E-9783-0ECDE10B0987Q36817045-CDB1F91B-5830-4B04-9E21-D80D47B726AFQ37427917-F8E35D02-667D-40FB-A405-3EE8A369864BQ37470623-8517184D-67A6-4DCF-A3C1-2732F369FE87Q37627897-CBBFC6E2-2844-4B58-9AF5-CE07DD83FD5CQ37715148-BE27E2DE-1A09-4985-B07B-F9416E2BC7DFQ37945219-D300E866-1E65-4908-A585-8D7607007111Q37984486-328465B8-9F1A-4DCD-804A-D3DCB0ADFC5FQ38016275-773E9405-80C9-43F5-832C-3058F85CF438Q38499923-C7EE3FEC-92A1-41FD-93DC-6A1CB1FD89E5Q38614156-9C24B012-3481-4E70-AB00-C61BD6074C19Q39220073-D40B73DC-75A4-4E69-AC22-3BE26B9BAFE3Q39797828-5542964C-D29B-48A8-A868-36BAC1B34E66Q41786777-7447324F-9099-43C5-8056-2B77106DFA33Q45855170-E700CCB3-E848-4C4C-8847-5582B0AA09BFQ45855508-1691866F-327D-4976-9676-E58D5EB79B9BQ45863838-35A320D0-695D-4AE4-9004-A22501708857Q45866594-066F71CC-CFC7-4729-A8F0-3C5907ECA402Q45875060-A9C40145-401B-417E-B41A-3BA2DF733ED3Q45875332-1B3AD7BB-BD44-447B-AAB0-A5265FD55DE0
P2860
Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Evaluation of toxicity from hi ...... -naive and pre-immunized mice.
@ast
Evaluation of toxicity from hi ...... -naive and pre-immunized mice.
@en
type
label
Evaluation of toxicity from hi ...... -naive and pre-immunized mice.
@ast
Evaluation of toxicity from hi ...... -naive and pre-immunized mice.
@en
prefLabel
Evaluation of toxicity from hi ...... -naive and pre-immunized mice.
@ast
Evaluation of toxicity from hi ...... -naive and pre-immunized mice.
@en
P2093
P2860
P356
P1433
P1476
Evaluation of toxicity from hi ...... r-naive and pre-immunized mice
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302347
P577
2005-03-01T00:00:00Z